Autosomal Dominant Polycystic Kidney Disease Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Autosomal Dominant Polycystic Kidney Disease remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 86 matched trial records and 128 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07651397 | Intervention not normalized | Not Applicable; Not yet recruiting | Assaf Harofeh Medical Center | Geography not listed | Change in Urinary MCP-1/Creatinine Ratio (Baseline and End of each 12-week study period (weeks 0,12, 18 and 30)) | 2029-01-01 |
| NCT07565441 | Rosuvastatin Calcium + Fluconazole + Cyclosporine | Phase 1; Not yet recruiting | Jiangxi Jemincare Group Co., Ltd. | Geography not listed | Maximum Plasma Concentration (Cmax) of JMKX003142 and its metabolites (for 120 hours); Area Under Curve (AUC) of JMKX003142 and its metabolites (for 120 hours) | 2026-11-15 |
| NCT07535385 | Intervention not normalized | Not Applicable; Recruiting | Sponsor not listed | Italy | Assessment of the radiological outcome of renal embolisation in terms of the reduction in the volume of the treated kidney as measured by MRI without contrast medium (up to 1 month, 3 months, 6 months and 12 months) | 2026-08-17 |
| JPRN-UMIN000061211 | Intervention not normalized | Not Applicable; 一般募集中/Open public recruiting | Tokyo Women's Medical University Educational Association | Japan | eGFR30%低下、eGFR50%低下、または腎代替療法導入の複合エンドポイント; Composite of a >=30% decline in eGFR, a >=50% decline in eGFR, or initiation of kidney replacement therapy | 2029-06-30 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver Disease (Phase 2/3): the indexed record reports Height-adjusted Total Liver Volume (htTLV)(Least Squares Mean) = 3.9 percentage (95% Confidence Interval, 0.1 - 7.7); Height-adjusted Total Liver Volume (htTLV)(Least Squares Mean): estimated relative treatment diff (%) = -4.3(95% CI, -8.4 to -0.1), P-Value = 0.0443; Height-adjusted Total Liver Volume (htTLV)(Least Squares Mean): estimated relative treatment diff (%) = -4.3(95% CI, -8.4 to -0.1), P-Value = 0.0443.
- Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD (Phase 1): the indexed record reports PC1 and PC2 = Increases in PC1 and PC2 were shown for 2, 3 mg/kg and 300 mg fixed doses versus placebo (p<0.05 for PC1 and PC2 for each dose).; PC1 and PC2 = Increases in PC1 and PC2 were shown for 2, 3 mg/kg and 300 mg fixed doses versus placebo (p<0.05 for PC1 and PC2 for each dose)..
- A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease (Phase 2): the indexed record reports HtTKV(annual change) = 3.1 % ( 1.4 - 6.8); HtTKV(annual change) = 4.3 % ( 3.0 - 6.6).
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Rosuvastatin Calcium (Approved; HMGCR), Fluconazole (Approved; CYP51A1), Cyclosporine (Approved; CaN). Company & Deal Intelligence records identify sponsor context for Assaf Harofeh Medical Center, Jiangxi Jemincare Group Co., Ltd., Tokyo Women's Medical University Educational Association. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Autosomal Dominant Polycystic Kidney Disease has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
